Biogen (NASDAQ: BIIB) is a biotechnology leader that discovers, develops and delivers to patients worldwide innovative therapies for the treatment of serious diseases.
Founded in 1978, Biogen is one of the world’s oldest independent biotechnology companies. Our development pipeline is focused on areas of high unmet medical need, as we pursue new therapies for diseases with few or no treatment options. These include programs for Alzheimer’s disease, Parkinson’s disease, spinal muscular atrophy, and amyotrophic lateral sclerosis (ALS), among others.
Biogen’s Cambridge headquarters is located in the center of the Boston-area academic community. We enjoy ties with many of the area’s world-class universities, and we also partner with leading academic institutions globally. We believe that collaborations between Biogen scientists and top academic researchers are critical to maintaining vibrant discovery and development programs.